Bbva Compass Bancshares Has Upped By $335748 Its Anika Therapeutics (ANIK) Stake; 5 Bullish Analysts Covering … – Key Gazette


October 28, 2017 – By Darrin Black

Bbva Compass Bancshares Inc increased Anika Therapeutics Inc (ANIK) stake by 83.79% reported in 2017Q2 SEC filing. Bbva Compass Bancshares Inc acquired 6,852 shares as Anika Therapeutics Inc (ANIK)’s stock declined 3.98%. The Bbva Compass Bancshares Inc holds 15,030 shares with $741,000 value, up from 8,178 last quarter. Anika Therapeutics Inc now has $816.18M valuation. The stock increased 1.51% or $0.83 on October 27, reaching $55.68. About 151,354 shares traded or 78.30% up from the average. Anika Therapeutics Inc (NASDAQ:ANIK) has risen 4.53% since October 28, 2016 and is uptrending. It has underperformed by 12.17% the S&P500.

Among 9 analysts covering Heico Corporation (NYSE:HEI), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. Heico Corporation had 28 analyst reports since August 24, 2015 according to SRatingsIntel. Canaccord Genuity maintained the stock with “Buy” rating in Tuesday, May 23 report. The stock of Heico Corp (NYSE:HEI) has “Hold” rating given on Friday, July 28 by Jefferies. The stock of Heico Corp (NYSE:HEI) has “Outperform” rating given on Thursday, December 15 by Credit Suisse. The rating was maintained by Canaccord Genuity with “Buy” on Friday, August 18. Canaccord Genuity maintained it with “Buy” rating and $9100 target in Thursday, August 10 report. The firm has “Hold” rating given on Tuesday, September 26 by Jefferies. The rating was downgraded by KeyBanc Capital Markets to “Sector Weight” on Friday, August 26. On Thursday, August 27 the stock rating was downgraded by Zacks to “Hold”. On Thursday, January 19 the stock rating was initiated by SunTrust with “Buy”. The rating was maintained by Canaccord Genuity with “Buy” on Thursday, August 27. See Heico Corp (NYSE:HEI) latest ratings:

24/10/2017 Broker: Canaccord Genuity Rating: Buy New Target: $95.0 Maintain
27/09/2017 Broker: Canaccord Genuity Rating: Buy New Target: $92.0 Maintain
26/09/2017 Broker: Jefferies Rating: Hold New Target: $89.0 Maintain
29/08/2017 Broker: Credit Suisse Rating: Outperform Old Target: $85 New Target: $98 Maintain
29/08/2017 Broker: Bank of America Old Rating: Neutral New Rating: Buy Upgrade
25/08/2017 Broker: Canaccord Genuity Rating: Buy Old Target: $91 New Target: $92 Maintain
23/08/2017 Broker: Jefferies Rating: Hold New Target: $89.0 Maintain
18/08/2017 Broker: Canaccord Genuity Rating: Buy New Target: $91.0 Maintain
17/08/2017 Broker: Deutsche Bank Old Rating: Buy New Rating: Hold Old Target: $100 Downgrade
10/08/2017 Broker: Canaccord Genuity Rating: Buy New Target: $91.0000 Maintain

Investors sentiment decreased to 1.14 in Q2 2017. Its down 0.12, from 1.26 in 2017Q1. It worsened, as 16 investors sold ANIK shares while 48 reduced holdings. 20 funds opened positions while 53 raised stakes. 12.24 million shares or 3.97% more from 11.77 million shares in 2017Q1 were reported. Tiaa Cref Investment Mngmt Limited Liability Corp invested in 39,359 shares. Jefferies Ltd Liability Corp invested 0% in Anika Therapeutics Inc (NASDAQ:ANIK). State Teachers Retirement System owns 0% invested in Anika Therapeutics Inc (NASDAQ:ANIK) for 11,166 shares. Cs Mckee Lp accumulated 14,100 shares or 0.06% of the stock. Citigroup Incorporated holds 0% or 18,955 shares in its portfolio. State Of Alaska Department Of Revenue holds 0.01% of its portfolio in Anika Therapeutics Inc (NASDAQ:ANIK) for 2,872 shares. Bbva Compass Bancorporation has invested 0.05% of its portfolio in Anika Therapeutics Inc (NASDAQ:ANIK). Alphamark Advisors Llc holds 0% or 3 shares. The North Carolina-based Atria Invs Limited Liability Co has invested 0.02% in Anika Therapeutics Inc (NASDAQ:ANIK). Ftb Advsrs reported 0% stake. Los Angeles Cap Mgmt & Equity invested 0.01% in Anika Therapeutics Inc (NASDAQ:ANIK). State Board Of Administration Of Florida Retirement has 7,943 shares for 0% of their portfolio. Gru One Trading LP invested in 0% or 1,200 shares. Prudential Financial Incorporated owns 24,900 shares. The Virginia-based Bb&T Ltd has invested 0.01% in Anika Therapeutics Inc (NASDAQ:ANIK).

Since May 19, 2017, it had 0 insider purchases, and 1 insider sale for $508,274 activity. 10,725 shares were sold by Thompson Jeffery S, worth $508,274 on Friday, May 19.

Bbva Compass Bancshares Inc decreased General Electric Company (NYSE:GE) stake by 25,121 shares to 370,608 valued at $10.01M in 2017Q2. It also reduced Ishares Msci Emerging Markets (EEM) stake by 12,015 shares and now owns 111,919 shares. Bristol (NYSE:BMY) was reduced too.

Among 3 analysts covering Anika Therapeutics (NASDAQ:ANIK), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Anika Therapeutics had 6 analyst reports since July 30, 2015 according to SRatingsIntel. The stock of Anika Therapeutics Inc (NASDAQ:ANIK) has “Market Perform” rating given on Wednesday, April 27 by Northland Capital. On Wednesday, August 26 the stock rating was upgraded by Zacks to “Hold”. The firm has “Outperform” rating by Barrington Research given on Monday, October 12. Northland Capital maintained Anika Therapeutics Inc (NASDAQ:ANIK) on Thursday, July 30 with “Outperform” rating. First Analysis initiated the stock with “Equal Weight” rating in Friday, August 28 report. The stock of Anika Therapeutics Inc (NASDAQ:ANIK) has “Outperform” rating given on Friday, February 26 by Northland Capital.

HEICO Corporation manufactures Federal Aviation Administration -approved jet engine and aircraft component replacement parts, other than the original equipment manufacturers (OEMs) and their subcontractors. The company has market cap of $6.98 billion. The Firm also makes various types of electronic equipment for the aviation, medical, telecommunications and electronics industries. It has a 44.6 P/E ratio. It operates through two divisions: Flight Support Group (FSG) and Electronic Technologies Group (ETG).

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *